Systemic therapy in younger and elderly patients with advanced biliary cancer: sub-analysis of ABC-02 and twelve other prospective trials.
Identifieur interne : 000E41 ( PubMed/Corpus ); précédent : 000E40; suivant : 000E42Systemic therapy in younger and elderly patients with advanced biliary cancer: sub-analysis of ABC-02 and twelve other prospective trials.
Auteurs : Mairéad Geraldine Mcnamara ; John Bridgewater ; Andre Lopes ; Harpreet Wasan ; David Malka ; Lars Henrik Jensen ; Takuji Okusaka ; Jennifer J. Knox ; Dorothea Wagner ; David Cunningham ; Jenny Shannon ; David Goldstein ; Markus Moehler ; Tanios Bekaii-Saab ; Juan W. ValleSource :
- BMC cancer [ 1471-2407 ] ; 2017.
English descriptors
- KwdEn :
- Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols (administration & dosage), Antineoplastic Combined Chemotherapy Protocols (therapeutic use), Biliary Tract Neoplasms (drug therapy), Biliary Tract Neoplasms (pathology), Carboplatin (administration & dosage), Carboplatin (therapeutic use), Cisplatin (administration & dosage), Cisplatin (therapeutic use), Disease-Free Survival, Female, Humans, Male, Middle Aged, Prospective Studies, Survival Analysis, Treatment Outcome, Young Adult.
- MESH :
- chemical , administration & dosage : Carboplatin, Cisplatin.
- administration & dosage : Antineoplastic Combined Chemotherapy Protocols.
- drug therapy : Biliary Tract Neoplasms.
- pathology : Biliary Tract Neoplasms.
- therapeutic use : Antineoplastic Combined Chemotherapy Protocols, Carboplatin, Cisplatin.
- Adult, Aged, Aged, 80 and over, Disease-Free Survival, Female, Humans, Male, Middle Aged, Prospective Studies, Survival Analysis, Treatment Outcome, Young Adult.
Abstract
Outcomes in younger (<40 years) and elderly (≥70 years) patients with advanced biliary cancer (ABC) receiving palliative chemotherapy are unclear. This study assessed outcomes in those receiving monotherapy or combination therapy in thirteen prospective systemic-therapy trials.
DOI: 10.1186/s12885-017-3266-9
PubMed: 28403829
Links to Exploration step
pubmed:28403829Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Systemic therapy in younger and elderly patients with advanced biliary cancer: sub-analysis of ABC-02 and twelve other prospective trials.</title>
<author><name sortKey="Mcnamara, Mairead Geraldine" sort="Mcnamara, Mairead Geraldine" uniqKey="Mcnamara M" first="Mairéad Geraldine" last="Mcnamara">Mairéad Geraldine Mcnamara</name>
<affiliation><nlm:affiliation>Division of Molecular & Clinical Cancer Sciences, Institute of Cancer Sciences, The University of Manchester and The Christie NHS Foundation Trust, Manchester, M20 4BX, UK. Mairead.McNamara@christie.nhs.uk.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Bridgewater, John" sort="Bridgewater, John" uniqKey="Bridgewater J" first="John" last="Bridgewater">John Bridgewater</name>
<affiliation><nlm:affiliation>UCL Cancer Institute, London, WCIE 6BT, UK.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Lopes, Andre" sort="Lopes, Andre" uniqKey="Lopes A" first="Andre" last="Lopes">Andre Lopes</name>
<affiliation><nlm:affiliation>Cancer Research UK & UCL Cancer Trials Centre, London, WCIE 6BT, UK.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Wasan, Harpreet" sort="Wasan, Harpreet" uniqKey="Wasan H" first="Harpreet" last="Wasan">Harpreet Wasan</name>
<affiliation><nlm:affiliation>Imperial Healthcare, London, WI2 ONN, UK.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Malka, David" sort="Malka, David" uniqKey="Malka D" first="David" last="Malka">David Malka</name>
<affiliation><nlm:affiliation>Institute Gustave Roussy, 94805, Villejuif, France.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Jensen, Lars Henrik" sort="Jensen, Lars Henrik" uniqKey="Jensen L" first="Lars Henrik" last="Jensen">Lars Henrik Jensen</name>
<affiliation><nlm:affiliation>Vejle Hospital, 7100, Vejle, Denmark.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Okusaka, Takuji" sort="Okusaka, Takuji" uniqKey="Okusaka T" first="Takuji" last="Okusaka">Takuji Okusaka</name>
<affiliation><nlm:affiliation>National Cancer Center Hospital, Tokyo, 104-0045, Japan.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Knox, Jennifer J" sort="Knox, Jennifer J" uniqKey="Knox J" first="Jennifer J" last="Knox">Jennifer J. Knox</name>
<affiliation><nlm:affiliation>Princess Margaret Cancer Centre, Toronto, M5G 2M9, Canada.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Wagner, Dorothea" sort="Wagner, Dorothea" uniqKey="Wagner D" first="Dorothea" last="Wagner">Dorothea Wagner</name>
<affiliation><nlm:affiliation>Centre Hospitalier Universitaire Vaudois, CH-1011, Lausanne, Switzerland.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Cunningham, David" sort="Cunningham, David" uniqKey="Cunningham D" first="David" last="Cunningham">David Cunningham</name>
<affiliation><nlm:affiliation>Royal Marsden Hospital, London, UK.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Shannon, Jenny" sort="Shannon, Jenny" uniqKey="Shannon J" first="Jenny" last="Shannon">Jenny Shannon</name>
<affiliation><nlm:affiliation>University of Sydney, Sydney, NSW, 2006, Australia.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Goldstein, David" sort="Goldstein, David" uniqKey="Goldstein D" first="David" last="Goldstein">David Goldstein</name>
<affiliation><nlm:affiliation>Prince of Wales Clinical School, University of New South Wales, Sydney, NSW, 2052, Australia.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Moehler, Markus" sort="Moehler, Markus" uniqKey="Moehler M" first="Markus" last="Moehler">Markus Moehler</name>
<affiliation><nlm:affiliation>Universitätsmedizin Mainz, 55122, Mainz, Germany.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Bekaii Saab, Tanios" sort="Bekaii Saab, Tanios" uniqKey="Bekaii Saab T" first="Tanios" last="Bekaii-Saab">Tanios Bekaii-Saab</name>
<affiliation><nlm:affiliation>Mayo Clinic, Phoenix, AZ, 85054, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Valle, Juan W" sort="Valle, Juan W" uniqKey="Valle J" first="Juan W" last="Valle">Juan W. Valle</name>
<affiliation><nlm:affiliation>Division of Molecular & Clinical Cancer Sciences, Institute of Cancer Sciences, The University of Manchester and The Christie NHS Foundation Trust, Manchester, M20 4BX, UK.</nlm:affiliation>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2017">2017</date>
<idno type="RBID">pubmed:28403829</idno>
<idno type="pmid">28403829</idno>
<idno type="doi">10.1186/s12885-017-3266-9</idno>
<idno type="wicri:Area/PubMed/Corpus">000E41</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000E41</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Systemic therapy in younger and elderly patients with advanced biliary cancer: sub-analysis of ABC-02 and twelve other prospective trials.</title>
<author><name sortKey="Mcnamara, Mairead Geraldine" sort="Mcnamara, Mairead Geraldine" uniqKey="Mcnamara M" first="Mairéad Geraldine" last="Mcnamara">Mairéad Geraldine Mcnamara</name>
<affiliation><nlm:affiliation>Division of Molecular & Clinical Cancer Sciences, Institute of Cancer Sciences, The University of Manchester and The Christie NHS Foundation Trust, Manchester, M20 4BX, UK. Mairead.McNamara@christie.nhs.uk.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Bridgewater, John" sort="Bridgewater, John" uniqKey="Bridgewater J" first="John" last="Bridgewater">John Bridgewater</name>
<affiliation><nlm:affiliation>UCL Cancer Institute, London, WCIE 6BT, UK.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Lopes, Andre" sort="Lopes, Andre" uniqKey="Lopes A" first="Andre" last="Lopes">Andre Lopes</name>
<affiliation><nlm:affiliation>Cancer Research UK & UCL Cancer Trials Centre, London, WCIE 6BT, UK.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Wasan, Harpreet" sort="Wasan, Harpreet" uniqKey="Wasan H" first="Harpreet" last="Wasan">Harpreet Wasan</name>
<affiliation><nlm:affiliation>Imperial Healthcare, London, WI2 ONN, UK.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Malka, David" sort="Malka, David" uniqKey="Malka D" first="David" last="Malka">David Malka</name>
<affiliation><nlm:affiliation>Institute Gustave Roussy, 94805, Villejuif, France.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Jensen, Lars Henrik" sort="Jensen, Lars Henrik" uniqKey="Jensen L" first="Lars Henrik" last="Jensen">Lars Henrik Jensen</name>
<affiliation><nlm:affiliation>Vejle Hospital, 7100, Vejle, Denmark.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Okusaka, Takuji" sort="Okusaka, Takuji" uniqKey="Okusaka T" first="Takuji" last="Okusaka">Takuji Okusaka</name>
<affiliation><nlm:affiliation>National Cancer Center Hospital, Tokyo, 104-0045, Japan.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Knox, Jennifer J" sort="Knox, Jennifer J" uniqKey="Knox J" first="Jennifer J" last="Knox">Jennifer J. Knox</name>
<affiliation><nlm:affiliation>Princess Margaret Cancer Centre, Toronto, M5G 2M9, Canada.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Wagner, Dorothea" sort="Wagner, Dorothea" uniqKey="Wagner D" first="Dorothea" last="Wagner">Dorothea Wagner</name>
<affiliation><nlm:affiliation>Centre Hospitalier Universitaire Vaudois, CH-1011, Lausanne, Switzerland.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Cunningham, David" sort="Cunningham, David" uniqKey="Cunningham D" first="David" last="Cunningham">David Cunningham</name>
<affiliation><nlm:affiliation>Royal Marsden Hospital, London, UK.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Shannon, Jenny" sort="Shannon, Jenny" uniqKey="Shannon J" first="Jenny" last="Shannon">Jenny Shannon</name>
<affiliation><nlm:affiliation>University of Sydney, Sydney, NSW, 2006, Australia.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Goldstein, David" sort="Goldstein, David" uniqKey="Goldstein D" first="David" last="Goldstein">David Goldstein</name>
<affiliation><nlm:affiliation>Prince of Wales Clinical School, University of New South Wales, Sydney, NSW, 2052, Australia.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Moehler, Markus" sort="Moehler, Markus" uniqKey="Moehler M" first="Markus" last="Moehler">Markus Moehler</name>
<affiliation><nlm:affiliation>Universitätsmedizin Mainz, 55122, Mainz, Germany.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Bekaii Saab, Tanios" sort="Bekaii Saab, Tanios" uniqKey="Bekaii Saab T" first="Tanios" last="Bekaii-Saab">Tanios Bekaii-Saab</name>
<affiliation><nlm:affiliation>Mayo Clinic, Phoenix, AZ, 85054, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Valle, Juan W" sort="Valle, Juan W" uniqKey="Valle J" first="Juan W" last="Valle">Juan W. Valle</name>
<affiliation><nlm:affiliation>Division of Molecular & Clinical Cancer Sciences, Institute of Cancer Sciences, The University of Manchester and The Christie NHS Foundation Trust, Manchester, M20 4BX, UK.</nlm:affiliation>
</affiliation>
</author>
</analytic>
<series><title level="j">BMC cancer</title>
<idno type="eISSN">1471-2407</idno>
<imprint><date when="2017" type="published">2017</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term>
<term>Aged</term>
<term>Aged, 80 and over</term>
<term>Antineoplastic Combined Chemotherapy Protocols (administration & dosage)</term>
<term>Antineoplastic Combined Chemotherapy Protocols (therapeutic use)</term>
<term>Biliary Tract Neoplasms (drug therapy)</term>
<term>Biliary Tract Neoplasms (pathology)</term>
<term>Carboplatin (administration & dosage)</term>
<term>Carboplatin (therapeutic use)</term>
<term>Cisplatin (administration & dosage)</term>
<term>Cisplatin (therapeutic use)</term>
<term>Disease-Free Survival</term>
<term>Female</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Prospective Studies</term>
<term>Survival Analysis</term>
<term>Treatment Outcome</term>
<term>Young Adult</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Carboplatin</term>
<term>Cisplatin</term>
</keywords>
<keywords scheme="MESH" qualifier="administration & dosage" xml:lang="en"><term>Antineoplastic Combined Chemotherapy Protocols</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Biliary Tract Neoplasms</term>
</keywords>
<keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Biliary Tract Neoplasms</term>
</keywords>
<keywords scheme="MESH" qualifier="therapeutic use" xml:lang="en"><term>Antineoplastic Combined Chemotherapy Protocols</term>
<term>Carboplatin</term>
<term>Cisplatin</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adult</term>
<term>Aged</term>
<term>Aged, 80 and over</term>
<term>Disease-Free Survival</term>
<term>Female</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Prospective Studies</term>
<term>Survival Analysis</term>
<term>Treatment Outcome</term>
<term>Young Adult</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Outcomes in younger (<40 years) and elderly (≥70 years) patients with advanced biliary cancer (ABC) receiving palliative chemotherapy are unclear. This study assessed outcomes in those receiving monotherapy or combination therapy in thirteen prospective systemic-therapy trials.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">28403829</PMID>
<DateCreated><Year>2017</Year>
<Month>04</Month>
<Day>13</Day>
</DateCreated>
<DateCompleted><Year>2017</Year>
<Month>06</Month>
<Day>12</Day>
</DateCompleted>
<DateRevised><Year>2017</Year>
<Month>06</Month>
<Day>12</Day>
</DateRevised>
<Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1471-2407</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>17</Volume>
<Issue>1</Issue>
<PubDate><Year>2017</Year>
<Month>Apr</Month>
<Day>12</Day>
</PubDate>
</JournalIssue>
<Title>BMC cancer</Title>
<ISOAbbreviation>BMC Cancer</ISOAbbreviation>
</Journal>
<ArticleTitle>Systemic therapy in younger and elderly patients with advanced biliary cancer: sub-analysis of ABC-02 and twelve other prospective trials.</ArticleTitle>
<Pagination><MedlinePgn>262</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1186/s12885-017-3266-9</ELocationID>
<Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Outcomes in younger (<40 years) and elderly (≥70 years) patients with advanced biliary cancer (ABC) receiving palliative chemotherapy are unclear. This study assessed outcomes in those receiving monotherapy or combination therapy in thirteen prospective systemic-therapy trials.</AbstractText>
<AbstractText Label="METHODS" NlmCategory="METHODS">Multivariable analysis explored the impact of therapy on progression-free (PFS) and overall survival (OS) in two separate age cohort groups: <70 years and ≥70 years, and <40 years and ≥40 years.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">Overall, 1163 patients were recruited (Jan 1997-Dec 2013). Median age of entire cohort: 63 years (range 23-85); 36 (3%) were <40, 260 (22%); ≥70. Combination therapy was platinum-based in nine studies. Among patients <40 and ≥70 years, 23 (64%) and 182 (70%) received combination therapy, respectively. Median follow-up was 42 months (95%-CI 37-51). Median PFS for patients <40 and ≥40 years was 3.5 and 5.9 months (P = 0.12), and OS was 10.8 and 9.7 months, respectively (P = 0.55). Median PFS for those <70 and ≥70 years was 6.0 and 5.0 months (P = 0.53), and OS was 10.2 and 8.8 months, respectively (P = 0.08). For the entire cohort, PFS and OS were significantly better in those receiving combination therapy: Hazard Ratio [HR]-0.66, 95%-CI 0.58-0.76, P < 0.0001 and HR-0.72, 95%-CI 0.63-0.82, P < 0.0001, respectively; and in patients ≥70 years: HR-0.54 (95%-CI 0.38-0.77, P = 0.001) and HR-0.60 (95%-CI 0.43-0.85, P = 0.004), respectively. There was no evidence of interaction between age and treatment for PFS (P = 0.58, P = 0.66) or OS (P = 0.18, P = 0.75).</AbstractText>
<AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">In ABC, younger patients are rare, and survival in elderly patients in receipt of systemic therapy for advanced disease, whether monotherapy or combination therapy, is similar to that of non-elderly patients, therefore age alone should not influence decisions regarding treatment.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>McNamara</LastName>
<ForeName>Mairéad Geraldine</ForeName>
<Initials>MG</Initials>
<AffiliationInfo><Affiliation>Division of Molecular & Clinical Cancer Sciences, Institute of Cancer Sciences, The University of Manchester and The Christie NHS Foundation Trust, Manchester, M20 4BX, UK. Mairead.McNamara@christie.nhs.uk.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Bridgewater</LastName>
<ForeName>John</ForeName>
<Initials>J</Initials>
<AffiliationInfo><Affiliation>UCL Cancer Institute, London, WCIE 6BT, UK.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Lopes</LastName>
<ForeName>Andre</ForeName>
<Initials>A</Initials>
<AffiliationInfo><Affiliation>Cancer Research UK & UCL Cancer Trials Centre, London, WCIE 6BT, UK.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Wasan</LastName>
<ForeName>Harpreet</ForeName>
<Initials>H</Initials>
<AffiliationInfo><Affiliation>Imperial Healthcare, London, WI2 ONN, UK.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Malka</LastName>
<ForeName>David</ForeName>
<Initials>D</Initials>
<AffiliationInfo><Affiliation>Institute Gustave Roussy, 94805, Villejuif, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Jensen</LastName>
<ForeName>Lars Henrik</ForeName>
<Initials>LH</Initials>
<AffiliationInfo><Affiliation>Vejle Hospital, 7100, Vejle, Denmark.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Okusaka</LastName>
<ForeName>Takuji</ForeName>
<Initials>T</Initials>
<AffiliationInfo><Affiliation>National Cancer Center Hospital, Tokyo, 104-0045, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Knox</LastName>
<ForeName>Jennifer J</ForeName>
<Initials>JJ</Initials>
<AffiliationInfo><Affiliation>Princess Margaret Cancer Centre, Toronto, M5G 2M9, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Wagner</LastName>
<ForeName>Dorothea</ForeName>
<Initials>D</Initials>
<AffiliationInfo><Affiliation>Centre Hospitalier Universitaire Vaudois, CH-1011, Lausanne, Switzerland.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Cunningham</LastName>
<ForeName>David</ForeName>
<Initials>D</Initials>
<AffiliationInfo><Affiliation>Royal Marsden Hospital, London, UK.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Shannon</LastName>
<ForeName>Jenny</ForeName>
<Initials>J</Initials>
<AffiliationInfo><Affiliation>University of Sydney, Sydney, NSW, 2006, Australia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Goldstein</LastName>
<ForeName>David</ForeName>
<Initials>D</Initials>
<AffiliationInfo><Affiliation>Prince of Wales Clinical School, University of New South Wales, Sydney, NSW, 2052, Australia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Moehler</LastName>
<ForeName>Markus</ForeName>
<Initials>M</Initials>
<AffiliationInfo><Affiliation>Universitätsmedizin Mainz, 55122, Mainz, Germany.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Bekaii-Saab</LastName>
<ForeName>Tanios</ForeName>
<Initials>T</Initials>
<AffiliationInfo><Affiliation>Mayo Clinic, Phoenix, AZ, 85054, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Valle</LastName>
<ForeName>Juan W</ForeName>
<Initials>JW</Initials>
<AffiliationInfo><Affiliation>Division of Molecular & Clinical Cancer Sciences, Institute of Cancer Sciences, The University of Manchester and The Christie NHS Foundation Trust, Manchester, M20 4BX, UK.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2017</Year>
<Month>04</Month>
<Day>12</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>England</Country>
<MedlineTA>BMC Cancer</MedlineTA>
<NlmUniqueID>100967800</NlmUniqueID>
<ISSNLinking>1471-2407</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>BG3F62OND5</RegistryNumber>
<NameOfSubstance UI="D016190">Carboplatin</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>Q20Q21Q62J</RegistryNumber>
<NameOfSubstance UI="D002945">Cisplatin</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList><CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2010 Apr 8;362(14):1273-81</RefSource>
<PMID Version="1">20375404</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2011 Sep 1;29(25):3457-65</RefSource>
<PMID Version="1">21810685</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2015 Nov 10;33(32):3826-33</RefSource>
<PMID Version="1">26195697</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Eur J Cancer. 2014 Dec;50(18):3125-35</RefSource>
<PMID Version="1">25446376</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Ann Oncol. 2014 Feb;25(2):391-8</RefSource>
<PMID Version="1">24351397</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2011 Jun 10;29(17 ):2357-63</RefSource>
<PMID Version="1">21519026</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Cancer Chemother Pharmacol. 2016 Aug;78(2):361-7</RefSource>
<PMID Version="1">27335026</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Crit Rev Oncol Hematol. 2011 Oct;80(1):31-9</RefSource>
<PMID Version="1">21094052</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Br J Cancer. 2010 Aug 10;103(4):469-74</RefSource>
<PMID Version="1">20628385</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Cancer J. 2005 Nov-Dec;11(6):461-73</RefSource>
<PMID Version="1">16393480</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Oncotarget. 2015 Dec 29;6(42):44995-5004</RefSource>
<PMID Version="1">26575326</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Br J Cancer. 2005 May 9;92(9):1650-4</RefSource>
<PMID Version="1">15856037</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>BMC Cancer. 2015 May 06;15:359</RefSource>
<PMID Version="1">25943747</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Natl Cancer Inst. 2004 Feb 18;96(4):261-8</RefSource>
<PMID Version="1">14970275</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Cancer Chemother Pharmacol. 2011 Mar;67(3):519-25</RefSource>
<PMID Version="1">20461378</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Br J Cancer. 2009 Dec 1;101(11):1846-52</RefSource>
<PMID Version="1">19904267</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Am J Surg. 2004 Apr;187(4):559-63</RefSource>
<PMID Version="1">15041513</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Hepatogastroenterology. 2011 Mar-Apr;58(106):270-4</RefSource>
<PMID Version="1">21661380</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Br J Cancer. 2016 Apr 26;114(9):965-71</RefSource>
<PMID Version="1">27115567</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Oncologist. 2000;5(3):224-37</RefSource>
<PMID Version="1">10884501</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Lancet Oncol. 2014 Jul;15(8):819-28</RefSource>
<PMID Version="1">24852116</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Ann Oncol. 2013 May;24(5):1306-12</RefSource>
<PMID Version="1">23293115</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>CA Cancer J Clin. 2013 Jan;63(1):11-30</RefSource>
<PMID Version="1">23335087</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2012 May 20;30(15):1813-21</RefSource>
<PMID Version="1">22529258</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Gastroenterol Hepatol. 2014 Feb;29(2):403-8</RefSource>
<PMID Version="1">23869919</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2007 May 10;25(14):1824-31</RefSource>
<PMID Version="1">17488980</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Ann Oncol. 2012 Sep;23 (9):2341-6</RefSource>
<PMID Version="1">22367707</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2016 Jul 10;34(20):2366-71</RefSource>
<PMID Version="1">27185838</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Crit Rev Oncol Hematol. 2011 Sep;79(3):302-7</RefSource>
<PMID Version="1">20888781</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Cancer J. 2005 Nov-Dec;11(6):449-60</RefSource>
<PMID Version="1">16393479</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Ann Oncol. 2016 Jan;27(1):134-40</RefSource>
<PMID Version="1">26483051</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Acta Oncol. 2011 Apr;50(3):448-54</RefSource>
<PMID Version="1">20670085</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Cancer. 2007 Sep 15;110(6):1307-12</RefSource>
<PMID Version="1">17628484</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Oncology. 2012;82(3):175-9</RefSource>
<PMID Version="1">22433475</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>World J Surg Oncol. 2015 Feb 12;13:38</RefSource>
<PMID Version="1">25889848</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Cancer. 2012 Jul 1;118(13):3377-86</RefSource>
<PMID Version="1">22072065</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Lancet Oncol. 2013 Oct;14(11):1077-85</RefSource>
<PMID Version="1">24028813</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000971" MajorTopicYN="N">Antineoplastic Combined Chemotherapy Protocols</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D001661" MajorTopicYN="N">Biliary Tract Neoplasms</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
<QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016190" MajorTopicYN="N">Carboplatin</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002945" MajorTopicYN="N">Cisplatin</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018572" MajorTopicYN="N">Disease-Free Survival</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016019" MajorTopicYN="N">Survival Analysis</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Biliary cancer</Keyword>
<Keyword MajorTopicYN="N">Elderly</Keyword>
<Keyword MajorTopicYN="N">Prospective trials</Keyword>
<Keyword MajorTopicYN="N">Systemic therapy</Keyword>
<Keyword MajorTopicYN="N">Younger patients</Keyword>
</KeywordList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year>
<Month>12</Month>
<Day>23</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2017</Year>
<Month>04</Month>
<Day>05</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2017</Year>
<Month>4</Month>
<Day>14</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2017</Year>
<Month>4</Month>
<Day>14</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2017</Year>
<Month>6</Month>
<Day>13</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>epublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">28403829</ArticleId>
<ArticleId IdType="doi">10.1186/s12885-017-3266-9</ArticleId>
<ArticleId IdType="pii">10.1186/s12885-017-3266-9</ArticleId>
<ArticleId IdType="pmc">PMC5389161</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000E41 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 000E41 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Asie |area= AustralieFrV1 |flux= PubMed |étape= Corpus |type= RBID |clé= pubmed:28403829 |texte= Systemic therapy in younger and elderly patients with advanced biliary cancer: sub-analysis of ABC-02 and twelve other prospective trials. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:28403829" \ | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \ | NlmPubMed2Wicri -a AustralieFrV1
This area was generated with Dilib version V0.6.33. |